Second Chinese company found shipping APIs from a banned manufacturer

FDA China
The FDA has cited China's Lumis Global Pharmaceuticals in a warning letter for selling APIs it got from a supplier on the FDA import alert list, then facing COAs.

If the FDA has serious concerns about the APIs or drugs made at a facility outside the U.S., it often will place it on its import alert list to prevent the products from entering the U.S. But that is not a guarantee they won’t get in.

For the second time in recent months, the FDA has slapped a Chinese company with a warning letter after finding that it was buying products from a banned supplier, faking Certificates of Analysis (COA) and then shipping the APIs as their own.

RELATED: Chinese API company found faking CoAs, selling potentially tainted products

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

This time around, the warning letter was issued to Lumis Global Pharmaceuticals after a September 2016 inspection of its site in Wuhan. It said at least some of the APIs it was selling came from an unidentified supplier on the FDA import alert list.

Lumis would then generate a COA by copying and pasting information from the supplier into a document with its own letterhead and send that to customers.

“Omitting information from COA compromises supply-chain accountability and traceability, and may put consumers at risk,” the FDA said.

The warning listed a number of other violations tied to the faked documents and suggested the company hire a consultant if intends to keep shipping to the U.S.

It also dinked the company after it found unidentified material in the company’s “released for shipping” area. The investigator was told that this material was not going to be released to customers, but was in fact going to be destroyed. If that is the case, the FDA said the material should be relabeled and held under controls that would prevent its release.

It is the second time this year that a Chinese company has been warned about faking COAs and selling product from a banned supplier. In a January warning letter, the FDA made the same charges against the Suzhou Pharmaceutical Technology facility in Suzhou, Jiangsu Province. The FDA also noted that the company didn’t have a quality assurance unit to test the APIs it sells. Instead, it had salespeople sign off on the certificates, using the title "QC Director."

Suggested Articles

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.